Treasury Draft Would Extend Investment Restrictions to Biotechnology

The U.S. Department of the Treasury has proposed expanding the Outbound Investment Security Program to cover biotechnology, hypersonics, high-performance computing, and supercomputing. The draft would also add Cuba, Iran, North Korea, and Russia to China as countries of concern. Depending on the transaction and activity, covered investments by U.S. persons could face notification requirements or be prohibited. The proposal is not final, and Treasury has not established an effective date; that date will be set in the final rule.

For pharmaceutical companies and investors, the central procurement and business-planning issue is how the draft defines covered transaction structures. The supplied account indicates that standalone drug licenses appear outside the covered transaction types, but profit-sharing co-development arrangements and joint ventures remain uncertain. In particular, the draft’s treatment of a joint venture formed without a separate legal entity is consequential: companies should not assume that the absence of a newly incorporated entity resolves the regulatory question. The source material also points to investments connected with China, Hong Kong, or Macau as requiring careful review under the proposed framework.

The proposal could affect business development, investment screening, and the structuring of cross-border biotechnology partnerships. Teams should examine equity investments, licensing arrangements, co-development economics, and NewCo or other joint-venture structures against the draft’s language, while distinguishing proposed requirements from obligations currently in force. For government contractors and other organizations supporting biotechnology research or commercialization, the proposal is a policy signal to track when evaluating partner exposure, investment relationships, and compliance processes; it is not itself a contract award or solicitation.

The public comment period provides a direct opportunity to seek clarity before the rule is finalized. Comments are due December 7, 2026, 41 days after the October 27 publication date, and the final rule is expected by March 13, 2027. Biotechnology Innovation Organization Chief Executive Officer John Crowley cautioned against an overly broad approach, saying: “As Treasury considers comments on the proposed rule, we need to ensure that we do not have an overly broad approach that would create uncertainty for innovators and investors, and that may unintentionally risk weakening U.S. biotech competitiveness.” That concern highlights the balance Treasury must address between national-security objectives and preserving investment and innovation pathways.

• Scope expansion: Treasury proposes adding biotechnology, hypersonics, high-performance computing, and supercomputing to the outbound investment program.
• Countries of concern: The proposal would add Cuba, Iran, North Korea, and Russia alongside China.
• Potential requirements: Covered U.S.-person investments could be subject to notification or prohibition requirements, depending on the transaction.
• Structure review: Standalone drug licenses appear outside the covered types in the supplied account; co-development and joint ventures remain unclear.
• Entity question: The draft’s treatment of joint ventures formed without a separate legal entity warrants close review by legal and business-development teams.
• Related markets: Companies with China-, Hong Kong-, or Macau-linked biotechnology programs should assess whether their investment structures could fall within the proposal.
• Comment deadline: Interested companies and industry groups can submit comments to Treasury by December 7, 2026 to address unresolved distinctions.
• Final-rule timing: A final rule is expected by March 13, 2027; Treasury will establish the effective date in that rule.
• Named companies in source material: Pfizer, 3SBio, Innovent, K2 Therapeutics, and Antengene are identified in connection with the signal. The supplied material mentions Pfizer’s reported $100 million stake in 3SBio as an example discussed in commentary, not as a Treasury determination that the investment would be prohibited.
• Compliance posture: Treat the proposal as pending policy, monitor the rulemaking, and distinguish existing transaction obligations from requirements that may apply after finalization.